Khiron Opens First clinic in Europe with Zerenia™ Clinics UK

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the opening of Zerenia™ Clinics UK in London as its first International Zerenia™ clinic in Europe. This collectively brings the Company’s total clinic count to 15 globally. Both virtual and in-person appointments can be made via the website

Khiron in the United Kingdom
The company is pursuing a consistent approach to improve patient access to medical cannabis and to develop the market for medical cannabis treatments in the UK. The opening of Zerenia™ Clinics UK by an expert team is another step in this direction that expands Khiron’s presence in Europe, where medical cannabis sales have grown more than 6x since Q1 2021. Even though Germany will continue to dominate the European market for medical cannabis until at least 2024, industry consultants Prohibition Partners expect the UK medical cannabis market to show the most significant growth of any country in Europe by 2025.

Zerenia™ Clinics UK will build upon Khiron’s presence in the UK which started in 2019 when Khiron became a founding member and also the exclusive Latin American supplier for Project Twenty21 which offers a subsidized pricing model for patients in the program to help address barriers to access in the UK market. The Company continues to focus on medical training for healthcare professionals after receiving full Continuing Professional Development (“CPD”) accreditation for its digital educational platform, Khiron Academy, and brings its proprietary clinical data generated in LatAm to the UK.

The Zerenia™ Clinic model
In the initial phase of operations, Zerenia™ Clinics UK will focus on pain management and will then expand its therapeutic portfolio to other areas such as mental health, women´s health, neurology and oncology. Though prominently located in London’s famous Chelsea district, Zerenia™ Clinics UK will initially focus on supporting patients digitally (or via video-consultations) to enable streamlined access to patients across the UK, many of whom suffer from debilitating conditions. Zerenia™ Clinics UK follows the high-quality standards of personalised cannabinoid-based therapies and pursues precision-based medicine with the central goal to improve patient access to cannabinoid-based therapies.

In LatAm, the proven clinic model Zerenia™ is a patient-centered integrated care model combining traditional and complementary medicine with a focus on treatments with medical cannabis. The 14 Zerenia™ clinics in Colombia and Peru are known for their evidence-based treatments and highly professional applications with over 14,000 individual patients treated to date.

Franziska Katterbach, President Khiron Europe commented, “I am very excited about the opening of Zerenia™ Clinics UK in London with our very experienced local team. This is a great milestone for Khiron and will contribute significantly to the dynamics of developing a market for medical cannabis in the UK. From day one, it has been our goal to improve patient access to medical cannabis where suitable and also create evidence for the effectiveness and tolerability of medical cannabis; opening a UK cannabis clinic is just another logical step to serve patient’s and clinician’s needs.”

Primary Sponsor

Top Marijuana Blog